AI-Driven Multi-Omics Intelligence for Next-Generation Precision Medicine

Nexyra Advanced Research is a biomedical deeptech company that integrates explainable artificial intelligence with multi-omics data science—including genomics, transcriptomics, metabolomics, and microbiome analytics—to transform complex molecular data into clinically actionable knowledge. Based in the Madrid Science Park, Nexyra’s mission is to bridge the gap between omics data and translational medicine, accelerating the discovery of biomarkers, therapeutic targets, and digital diagnostics.

Current biomedical research faces a critical bottleneck: while omics technologies generate vast molecular datasets, most remain underutilized—over 80% of biomedical data does not translate into patient value (McKinsey, 2019). Nexyra solves this problem by providing a unified computational framework that integrates multi-omic layers using interpretable machine learning models. This enables clinicians and researchers to visualize the biological complexity of diseases and identify key regulatory pathways—turning data into precision insights.

The company’s proprietary AI pipelines model interactions across multiple biological systems, allowing early detection of molecular dysfunctions and prediction of therapy response. Nexyra’s work spans oncology, rare diseases, and longevity medicine—areas where molecular heterogeneity limits the success of standard diagnostics and therapies.

Nexyra has established strategic collaborations with leading institutions and biotech partners to validate its technology across diverse biomedical domains:

• Biotech – early-stage discussions and pilot integration for multi-omic biomarkers in oncology.

• UCAM HiTech & Prof. Juan Carlos Izpisúa Belmonte’s group – multi-omic research in mitochondrial and rare diseases, aligned with Altos Labs longevity programs.

• Development of molecular longevity signatures integrating telomere, exome, and microbiome data.

• Collaboration in the RedAI initiative, focusing on AI-driven omics analytics and data governance.

Scientific validation includes clinical pilot studies in oncology and rare metabolic disorders, alongside integrative analyses of human cohorts from public databases such as TCGA and CGGA. Nexyra’s approach combines statistical robustness with explainable AI, ensuring interpretability and reproducibility—key for clinical and regulatory adoption.

The company’s R&D portfolio spans several translational projects:

• Glioblastoma: adaptive metabolic biomarkers using transcriptomic–metabolomic integration.

• Pancreatic cancer (PDAC): multi-cohort meta-analysis identifying novel NF-κB inflammatory signatures.

• Mitochondrial diseases: multi-omic response tracking under NAD⁺-enhancing compounds.

• Precision longevity: profiling of biological aging pathways through integrative omics and circadian modeling.

This pipeline demonstrates Nexyra’s capability to translate molecular data into validated biomedical assets—from candidate biomarkers to patentable molecular signatures.